Outcomes of endovascular treatment for myocardial infarction and different phenotypes of coronary microvascular obstruction syndrome (slow-flow/no-reflow)
- 8 April 2026
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (2) , 49-57
Abstract
Objective. To study the outcomes of percutaneous coronary interventions (PCI) in patients with myocardial infarction (MI) and different phenotypes of coronary microvascular obstruction (CMVO). Material and methods. A single-center cohort study enrolled patients with type 1 MI who underwent PCI and developed CMVO (TIMI flow grade<3 or Myocardial blush grade<2 or no ST-segment resolution after PCI). Using the methodology by Frolov A.A. (2023), we classified patients depending on CMVO phenotypes. Patients with moderate coronary thrombosis (Thrombus Burden Classification grades 0—3) were assigned to atheroembolic phenotype. Among other patients with severe thrombosis (grades 4—5), those younger than 67 years were classified as microthromboembolic», those aged ≥67 years — age-associated. The median follow-up was 1036 [880; 1371] days. We analyzed survival rates across different phenotypes (Log-rank test) and performed multivariate analysis of mortality risk (weighted Cox regression). Results. A total of 190 patients were included. In-hospital mortality was 4.7% (n=9), and 29 (15.3%) ones died after discharge. Thus, the overall mortality rate was 20% (n=38). The probability of survival was comparable in microthromboembolic and atheroembolic phenotypes (0.78 and 0.79, respectively), but it was the lowest in age-associated phenotype (0.46, p<0.001). Multivariate analysis showed that age-associated phenotype was a predictor of death (hazard ratio 4.02, 95% confidence interval 1.56—10.3, p=0.004). Conclusion. Patients with MI and PCI complicated by distal thrombo- or atheroembolism have significant but comparable risk of death over the following years. Patients with age-associated phenotype have the worst prognosis.Keywords
This publication has 22 references indexed in Scilit:
- Prevalence and prognostic implications of the no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention in a university center in a middle-income countryEuropean Heart Journal, 2022
- Pathophysiology, Diagnosis, and Management of Coronary No-Reflow PhenomenonInternational Journal of Angiology, 2021
- Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionCoronary Artery Disease, 2019
- Reduction of No Reflow with a Loading Dose of Atorvastatin before Primary Angioplasty in Patients with Acute ST Myocardial InfarctionArchives of Medical Research, 2018
- Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factorsEuropean Radiology, 2018
- 5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial InfarctionJACC, 2010
- Microvascular ObstructionJACC, 2010
- Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarctionJACC, 2000
- Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial.Circulation, 1989
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985